Cresset Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $123K | Sell |
24,357
-520
| -2% | -$2.63K | ﹤0.01% | 1566 |
|
|
2025
Q1 | $132K | Sell |
24,877
-152
| -0.6% | -$804 | ﹤0.01% | 1567 |
|
|
2024
Q4 | $169K | Sell |
25,029
-45,663
| -65% | -$309K | ﹤0.01% | 1560 |
|
|
2024
Q3 | $466K | Sell |
70,692
-2,660
| -4% | -$17.5K | ﹤0.01% | 1526 |
|
|
2024
Q2 | $550K | Buy |
73,352
+9,791
| +15% | +$73.4K | ﹤0.01% | 1359 |
|
|
2024
Q1 | $634K | Buy |
63,561
+11,392
| +22% | +$114K | ﹤0.01% | 1199 |
|
|
2023
Q4 | $514K | Buy |
52,169
+37,092
| +246% | +$366K | ﹤0.01% | 1201 |
|
|
2023
Q3 | $115K | Buy |
+15,077
| New | +$115K | ﹤0.01% | 1659 |
|
|
2023
Q1 | – | Sell |
-46,861
| Closed | -$361K | – | 857 |
|
|
2022
Q4 | $361K | Hold |
46,861
| – | – | ﹤0.01% | 492 |
|
|
2022
Q3 | $499K | Hold |
46,861
| – | – | 0.01% | 512 |
|
|
2022
Q2 | $381K | Sell |
46,861
-156
| -0.3% | -$1.27K | ﹤0.01% | 640 |
|
|
2022
Q1 | $337K | Sell |
47,017
-86,420
| -65% | -$619K | ﹤0.01% | 732 |
|
|
2021
Q4 | $2.29M | Buy |
+133,437
| New | +$2.29M | 0.02% | 271 |
|